0 citations
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
SSRN Electronic Journal2021
Citations Over Time
Amy Flaxman, Natalie G. Marchevsky, Daniel Jenkin, Jeremy Aboagye, Parvinder K. Aley, Brian Angus, Sandra Belij‐Rammerstorfer, Sagida Bibi, Mustapha Bittaye, Federica Cappuccini, Paola Cicconi, Elizabeth Clutterbuck, Sophie Davies, Wanwisa Dejnirattisai, Christina Dold, Katie Ewer, Pedro M. Folegatti, Jamie Fowler, Adrian V. S. Hill, Simon Kerridge, Angela M. Minassian, Juthathip Mongkolspaya, Yama F Mujadidi, Emma Plested, Maheshi Ramasamy, Hannah Robinson, Helen Sanders, Emma Sheehan, Holly Smith, Matthew D. Snape, Rinn Song, Danielle Woods, Gavin Screaton, Sarah C. Gilbert, Merryn Voysey, Andrew J. Pollard, Teresa Lambe, The Oxford COVID Vaccine Group
Related Papers
- → Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England(2021)66 cited
- → Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1–11-year-old children(2005)19 cited
- [Evaluation of the safety, reactogenicity and antigenic activity of inactivated chromatographic influenza vaccine in school children].(1982)
- [Study of tolerability and reactogenicity of pandemic vaccines against influenza type A/H1N1].(2010)
- → Comparison of the reactogenicity and immunogenicity of two different dose levels of inactivated hepatitis a vaccine in healthy children and adolescents(1998)